These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 18672537

  • 21. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
    Nicot F, Alric L, Barange K, Métivier S, Dramard JM, Combis JM, Castan B, Meurisse JJ, Payen JL, Garipuy D, Desmorat H, Peron JM, Thebault S, Morin T, Renou C, Barel P, Guerin B, Imbert Y, Sire S, Sauné K, Chatelut E, Izopet J.
    J Med Virol; 2011 Mar; 83(3):437-44. PubMed ID: 21264864
    [Abstract] [Full Text] [Related]

  • 22. Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.
    Fujino T, Nakamuta M, Aoyagi Y, Kohjima M, Satoh T, Fukuda M, Ishibashi H, Yatsuhashi H, Enjoji M.
    Med Sci Monit; 2011 Dec; 17(12):CR687-91. PubMed ID: 22129899
    [Abstract] [Full Text] [Related]

  • 23. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR, Imoto S, Mita K, Taniguchi M, Sasase N, Muramatsu A, Kudo M, Kitai S, El-Shamy A, Hotta H, Hayashi Y.
    Digestion; 2009 Dec; 79(1):36-9. PubMed ID: 19246919
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
    Jara P, Hierro L, de la Vega A, Díaz C, Camarena C, Frauca E, Miños-Bartolo G, Díez-Dorado R, de Guevara CL, Larrauri J, Rueda M.
    Pediatr Infect Dis J; 2008 Feb; 27(2):142-8. PubMed ID: 18174875
    [Abstract] [Full Text] [Related]

  • 25. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
    Aghemo A, Rumi MG, Soffredini R, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M.
    Antivir Ther; 2006 Feb; 11(6):797-802. PubMed ID: 17310824
    [Abstract] [Full Text] [Related]

  • 26. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.
    Aghemo A, Rumi MG, Monico S, Prati GM, D'Ambrosio R, Donato MF, Colombo M.
    Antivir Ther; 2009 Feb; 14(4):577-84. PubMed ID: 19578243
    [Abstract] [Full Text] [Related]

  • 27. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients.
    Roomer R, Bergmann JF, Boonstra A, Hansen BE, Haagmans BL, Kwadijk-de Gijsel S, van Vuuren AJ, de Knegt RJ, Janssen HL.
    Antivir Ther; 2012 Feb; 17(3):509-17. PubMed ID: 22300892
    [Abstract] [Full Text] [Related]

  • 28. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
    Kawakami Y, Suzuki F, Karino Y, Toyota J, Kumada H, Chayama K.
    Antivir Ther; 2014 Feb; 19(3):277-85. PubMed ID: 24192751
    [Abstract] [Full Text] [Related]

  • 29. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
    Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P.
    J Viral Hepat; 2003 Jan; 10(1):37-42. PubMed ID: 12558910
    [Abstract] [Full Text] [Related]

  • 30. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
    Payan C, Pivert A, Morand P, Fafi-Kremer S, Carrat F, Pol S, Cacoub P, Perronne C, Lunel F, ANRS HC02 RIBAVIC study team.
    Gut; 2007 Aug; 56(8):1111-6. PubMed ID: 17363475
    [Abstract] [Full Text] [Related]

  • 31. An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1.
    Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Takagi M, Hiramatsu T, Hosokawa T, Arakawa T, Fujimori M.
    J Med Virol; 2010 Sep; 82(9):1537-44. PubMed ID: 20648607
    [Abstract] [Full Text] [Related]

  • 32. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    Gonçales FL, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R, Pavan MH, Gonçales NS.
    BMC Infect Dis; 2010 Jul 20; 10():212. PubMed ID: 20646277
    [Abstract] [Full Text] [Related]

  • 33. Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy.
    Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T, Tasaki K, Hirose S, Suzuki Y.
    Ther Apher Dial; 2011 Aug 20; 15(4):400-5. PubMed ID: 21884476
    [Abstract] [Full Text] [Related]

  • 34. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P, Slesinger P, Stroblová H, Svobodník A, Husová L.
    Klin Mikrobiol Infekc Lek; 2008 Apr 20; 14(2):67-73. PubMed ID: 18756436
    [Abstract] [Full Text] [Related]

  • 35. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
    Marcellin P, Horsmans Y, Nevens F, Grange JD, Bronowicki JP, Vetter D, Purdy S, Garg V, Bengtsson L, McNair L, Alam J.
    J Hepatol; 2007 Oct 20; 47(4):476-83. PubMed ID: 17629590
    [Abstract] [Full Text] [Related]

  • 36. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 37. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellón JM, Esteban H, GESIDA HIV/HCV cohort.
    J Antimicrob Chemother; 2009 Jun 02; 63(6):1256-63. PubMed ID: 19363085
    [Abstract] [Full Text] [Related]

  • 38. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A.
    J Viral Hepat; 2005 May 02; 12(3):292-9. PubMed ID: 15850470
    [Abstract] [Full Text] [Related]

  • 39. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.
    J Gastroenterol Hepatol; 2007 May 02; 22(5):669-75. PubMed ID: 17444854
    [Abstract] [Full Text] [Related]

  • 40. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M, Aizawa Y, Chuganji Y, Ishizuka H, Fujita Y, Aizawa R, Abe H, Matsuda T, Itou Y, Nakanishi H, Ushiyama H, Higuchi T, Fujimoto T, Endou H, Iga D, Ohta K, Kuroda H.
    J Gastroenterol Hepatol; 2006 Jul 02; 21(7):1177-83. PubMed ID: 16824072
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.